First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M - Tan, D S-W; Seto, T; Leighl, N B (ASCO Meet Abstr, 2015)
(Suppl): abstract 8013